What question did this study set out to answer?

To assess the efficacy of dupilumab in reducing daily symptom burden in patients with prurigo nodularis.

March 5, 2026Dermatology and Therapy0 citationsOpen Access

Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies

SKShawn G. KwatraUniversity of Maryland, Baltimore SSSonja StänderUniversity of Münster BKBrian S. KimIcahn School of Medicine at Mount Sinai

Key Points

To assess the efficacy of dupilumab in reducing daily symptom burden in patients with prurigo nodularis.
Post hoc analysis of LIBERTY PN-PRIME and PRIME2 studies
Comparison between dupilumab and placebo groups
Evaluation of symptom improvement in itch, skin pain, and sleep disturbance.
Patients on dupilumab experienced greater improvement in daily symptom burden (DSB)
Significant reductions in itch, skin pain, and sleep disturbances compared to placebo.

Abstract

Patients treated with dupilumab showed greater improvement in DSB with respect to itch, skin pain, and sleep disturbance than those receiving placebo.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper